# Liposome-based drug delivery systems for skin wound healing: a promising drug delivery strategy

**Authors:** Zhensheng Ma, Kaiying Zhang, Jiayu Luo, Shuoling Chen, Shenglong Tan, Dandan Ma

PMC · DOI: 10.3389/fbioe.2026.1756872 · Frontiers in Bioengineering and Biotechnology · 2026-02-12

## TL;DR

This review explores how liposome-based drug delivery systems can improve skin wound healing and their potential for future clinical use.

## Contribution

The paper provides a comprehensive review of liposome-based delivery systems tailored for skin wound healing and their clinical translational potential.

## Key findings

- Liposome-based systems offer advantages in promoting skin wound healing.
- Various materials and technologies have been integrated to enhance liposome efficacy.
- The review suggests future applications and research directions for these systems.

## Abstract

Skin wound healing remains a significant challenge in clinical medicine. Liposomes (LPs), as a versatile drug delivery system, have garnered widespread attention for their potential in promoting skin wound healing. However, the limitations of conventional LPs have hindered their broader clinical applications. To enhance the efficacy of LPs, researchers have developed various liposome-based delivery systems (LPs-DS) by integrating different materials and technologies. This review focuses on the field of skin wounds, highlighting the advantages of LPs-DS and clinical translational concepts in promoting skin wound healing. It summarizes their applications in different types of wounds and suggests potential future applications, aiming to provide a reference for further research on drug delivery systems.

## Full-text entities

- **Genes:** HMGB1 (high mobility group box 1) [NCBI Gene 445521], CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, Gal (galanin and GMAP prepropeptide) [NCBI Gene 14419] {aka Galn}, GAL (galanin and GMAP prepropeptide) [NCBI Gene 51083] {aka ETL8, GAL-GMAP, GALN, GLNN, GMAP}, Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 60628], Keap1 (Kelch-like ECH-associated protein 1) [NCBI Gene 117519] {aka Inrf2}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Ackr3 (atypical chemokine receptor 3) [NCBI Gene 84348] {aka Cmkor1, Cxcr7, Rdc1}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, Cxcl12 (C-X-C motif chemokine ligand 12) [NCBI Gene 24772] {aka Sdf1}
- **Diseases:** MRSA (MESH:D013203), neuropathy (MESH:D009422), skin defects (MESH:D012868), hypoxia (MESH:D000860), systemic diseases (MESH:D034721), Burns (MESH:D002056), chronic (MESH:D002908), osteoarthritis (MESH:D010003), ischemia (MESH:D007511), necrosis (MESH:D009336), erythema (MESH:D004890), acute wounds (MESH:D000208), acne (MESH:D000152), frostbite (MESH:D005627), peripheral neuropathy (MESH:D010523), retinal diseases (MESH:D012164), bacterial (MESH:D001424), hypoxic (MESH:D002534), bleeding (MESH:D006470), breast cancer (MESH:D001943), toxicity (MESH:D064420), infected wounds (MESH:D014946), subcutaneous (MESH:D013352), blood loss (MESH:D016063), DM (MESH:D009223), Infection (MESH:D007239), skin leishmaniasis (MESH:D007896), thermal injuries (MESH:D020886), cancer (MESH:D009369), Diabetic (MESH:D003920), ischemic (MESH:D002545), breast and ovarian cancers (MESH:D061325), death (MESH:D003643), pain (MESH:D010146), pancreatic cancer (MESH:D010190), skin injuries (MESH:D000069836), skin damage (MESH:D012871), inflammation (MESH:D007249), Skin wounds (MESH:D014947), diabetic foot complications (MESH:D017719), neurodegenerative diseases (MESH:D019636), hyperglycemia (MESH:D006943), Pressure ulcers (MESH:D003668), glioma (MESH:D005910)
- **Chemicals:** lecithin (MESH:D054709), glucose (MESH:D005947), PVP-I (MESH:D011206), methicillin (MESH:D008712), Ethanol (MESH:D000431), ROS (MESH:D017382), hyaluronic acid (MESH:D006820), valsartan (MESH:D000068756), blood glucose (MESH:D001786), Carbopol (MESH:C006912), Fucidin (MESH:D005672), Ag+ (MESH:D012834), Resveratrol (MESH:D000077185), chlorhexidine (MESH:D002710), lipid (MESH:D008055), PTX (MESH:D010431), LPS (MESH:D008070), vancomycin (MESH:D014640), iodine (MESH:D007455), catechin (MESH:D002392), phospholipid (MESH:D010743), H2O (MESH:D014867), CS (MESH:D002586), imipenem (MESH:D015378), HMME (MESH:C494379), TL (MESH:D013793), DCPA (MESH:C007220), PVA (MESH:C063253), ciprofloxacin (MESH:D002939), Pg (MESH:D019946), Silver Sulfadiazine (MESH:D012837), polymer (MESH:D011108), tranilast (MESH:C012293), polyvinyl alcohol (MESH:D011142), Panthenol (MESH:C007288), Madecassoside (MESH:C093443), cyclodextrin (MESH:D003505), polyethylene glycol (MESH:D011092), Chitosan (MESH:D048271), Pluronic F127 (MESH:D020442), phosphate (MESH:D010710), PS (MESH:D010758), doxorubicin (MESH:D004317), Citicoline (MESH:D003566), sugars (MESH:D000073893), Cypate (MESH:C000604523), taxifolin (MESH:C003377), oxygen (MESH:D010100), alginate (MESH:D000464), DS (MESH:D003903), Garvicin KS (-), gold (MESH:D006046)
- **Species:** Sus scrofa (pig, species) [taxon 9823], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280], Rattus norvegicus (brown rat, species) [taxon 10116], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936863/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936863/full.md

## References

186 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936863/full.md

---
Source: https://tomesphere.com/paper/PMC12936863